UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risperidone for autism spectrum disorder

Cochrane database of systematic reviews, 2007-01, Vol.2010 (1), p.CD005040

2007

Volltextzugriff (PDF)

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone

The journal of clinical psychiatry, 2009-04, Vol.70 (4), p.487-499

2009

Volltextzugriff (PDF)

Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm

JAMA psychiatry (Chicago, Ill.), 2015-05, Vol.72 (5), p.438

2015

Volltextzugriff (PDF)

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

JAMA : the journal of the American Medical Association, 2009-10, Vol.302 (16), p.1765

2009

Volltextzugriff (PDF)

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

Schizophrenia research, 2010-11, Vol.123 (2), p.225-233

2010

Volltextzugriff (PDF)

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

The journal of clinical psychiatry, 2003-10, Vol.64 (10), p.1250-1257

2003

Volltextzugriff (PDF)

A systematic review of medical treatments for children with autism spectrum disorders

Pediatrics (Evanston), 2011-05, Vol.127 (5), p.e1312-e1321

2011

Volltextzugriff (PDF)

Antipsychotics for treatment of delirium in hospitalised non-ICU patients

Cochrane database of systematic reviews, 2018-06, Vol.6 (6), p.CD005594

2018

Volltextzugriff (PDF)

Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome

Psychopharmacology, 2019-05, Vol.236 (5), p.1491-1512

2019

Volltextzugriff (PDF)

Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations

JAMA psychiatry (Chicago, Ill.), 2016-09, Vol.73 (9), p.938

2016

Volltextzugriff (PDF)

Risk of Mortality Among Individual Antipsychotics in Patients With Dementia

The American journal of psychiatry, 2012-01, Vol.169 (1), p.71-79

2012

Volltextzugriff (PDF)

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

The New England journal of medicine, 2005-09, Vol.353 (12), p.1209-1223

2005

Volltextzugriff (PDF)

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

The international journal of neuropsychopharmacology, 2020-04, Vol.23 (4), p.217-229

2020

Volltextzugriff (PDF)

Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study

BMJ, 2012-02, Vol.344 (feb23 2), p.e977-e977

International edition, 2012

Volltextzugriff (PDF)

The side effect profile of Clozapine in real world data of three large mental health hospitals

PloS one, 2020-12, Vol.15 (12), p.e0243437

2020

Volltextzugriff (PDF)

Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis

Schizophrenia research, 2024-09, Vol.271, p.371-379

2024

Volltextzugriff (PDF)

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia

Cochrane database of systematic reviews, 2021-12, Vol.12 (1), p.CD013304

2021

Volltextzugriff (PDF)

A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes

Schizophrenia bulletin, 2015-11, Vol.41 (6), p.1227-1236

2015

Volltextzugriff (PDF)

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study

JAMA psychiatry (Chicago, Ill.), 2015-09, Vol.72 (9), p.927

2015

Volltextzugriff (PDF)

Acetylcholinesterase inhibitors for autistic spectrum disorders

Cochrane database of systematic reviews, 2023-06, Vol.6 (6), p.CD013851-CD013851

2023

Volltextzugriff (PDF)

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study

Schizophrenia research, 2016-04, Vol.172 (1-3), p.152-157

2016

Volltextzugriff (PDF)

Comparative efficacy and safety of olanzapine and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease: Systematic review and meta-analysis

Medicine (Baltimore), 2024-07, Vol.103 (27), p.e35663

2024

Volltextzugriff (PDF)

Atypical antipsychotics for disruptive behaviour disorders in children and youths

Cochrane database of systematic reviews, 2017-08, Vol.8 (8), p.CD008559

2017

Volltextzugriff (PDF)

Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization

Journal of the American Academy of Child and Adolescent Psychiatry, 2021-02, Vol.60 (2), p.236-251

2021

Volltextzugriff (PDF)

Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety

Journal of clinical psychopharmacology, 2016-06, Vol.36 (3), p.244-252

Uguz, Faruk

2016

Volltextzugriff (PDF)

1 – 25 von 3.104

Suche als RSS-Feed

Aktive Filter

SpracheItalienisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.908)
Mit Volltextzugriff
(1.942)

Publikationsform

Sprache

13 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(2.967)
Science & Technology
(2.573)
Life Sciences & Biomedicine
(2.549)
Antipsychotic Agents - Adverse Effects
(2.527)
Risperidone - Adverse Effects
(2.382)
Male
(1.954)
Psychiatry
(1.865)
Female
(1.764)
Risperidone - Therapeutic Use
(1.613)
Antipsychotic Agents - Therapeutic Use
(1.607)
Adult
(1.402)
Schizophrenia - Drug Therapy
(1.275)
Risperidone
(1.130)
Pharmacology & Pharmacy
(1.014)
Biological And Medical Sciences
(957)
Medical Sciences
(950)
Middle Aged
(935)
Pharmacology. Drug Treatments
(860)
Schizophrenia
(767)
Treatment Outcome
(679)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Risperidone for autism spectrum disorder

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone

Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

A systematic review of medical treatments for children with autism spectrum disorders

Antipsychotics for treatment of delirium in hospitalised non-ICU patients

Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome

Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations

Risk of Mortality Among Individual Antipsychotics in Patients With Dementia

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study

The side effect profile of Clozapine in real world data of three large mental health hospitals

Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia

A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study

Acetylcholinesterase inhibitors for autistic spectrum disorders

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study

Comparative efficacy and safety of olanzapine and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease: Systematic review and meta-analysis

Atypical antipsychotics for disruptive behaviour disorders in children and youths

Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization

Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety

Aktive Filter

Suchergebnisse filtern